Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% ...
The long-lived SUV is available with a new 324-hp Hurricane 4 turbo engine, and it feels like an upgrade.
Facilitating the integration of domestic SMEs into the supplier chains of the largest international companies is one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results